Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Multiple-drug Resistance Clear all
Completed Phase 1 Interventional

Study of TPI 287 in Patients With Advanced Malignancies

NCT00113724
View directory record Official record
Conditions
Neoplasms, Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
TPI 287 Injection
Drug
Lead sponsor
Cortice Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Sep 17, 2026, 5:15 AM EDT
Not yet recruiting Phase 2 Interventional

A Clinical Trial of Resistant Potato Starch for Gut MDRO Decolonization

NCT07792915
View directory record Official record
Conditions
Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococci, Carbapenem-Resistant Enterobacteriaceae, Asymptomatic Infections
Interventions
Resistant Potato Starch, Maltodextrin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional

Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance

NCT00187551
View directory record Official record
Conditions
HIV Infections
Interventions
Interruption of enfuvirtide, enfuvirtide interrupton
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2011 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

NCT05526911
View directory record Official record
Conditions
Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis, Drug Sensitive Tuberculosis, Drug-resistant Tuberculosis, Mycobacterium Tuberculosis Infection
Interventions
TBAJ-876, Midazolam, Digoxin
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Not applicable Interventional

VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms

NCT03944369
View directory record Official record
Conditions
Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects
Interventions
KB109, No intervention
Other
Lead sponsor
Kaleido Biosciences
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Torrance, California • Atlanta, Georgia • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833

NCT00001302
View directory record Official record
Conditions
Breast Cancer, Kidney Neoplasm, Lymphoma, Neoplasm Metastasis, Ovarian Cancer
Interventions
PSC 833
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Multi-Drug Resistant Organism (MDRO): Study of Highly Resistant Escherichia Coli

NCT04574596
View directory record Official record
Conditions
E Coli Infection
Interventions
no Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
300 participants
Timeline
2020 – 2021
U.S. locations
13
States / cities
Torrance, California • Aurora, Colorado • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
AZD0516, AZD9574
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
Fayetteville, Arkansas • Los Angeles, California • Towson, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Aerosolized and Intravenous Colistin in Healthy Adults

NCT01863719
View directory record Official record
Conditions
Pathogen Resistance, Pneumococcal Infection, Pneumonia
Interventions
Colistimethate sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study of SQ109 in Healthy Adult Volunteers

NCT00866190
View directory record Official record
Conditions
TB Multi-drug Resistant
Interventions
SQ109, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies

NCT01068860
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Canakinumab 150 mg, Placebo to Canakinumab
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
11
States / cities
Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2011 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pilot Study of 18F Fluoropaclitaxel (FPAC)

NCT00572598
View directory record Official record
Conditions
Breast Cancer
Interventions
4- [F-18] fluoropaclitaxel
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 90 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Sep 17, 2026, 5:15 AM EDT
Available No phase listed Expanded access

Epidiolex and Drug Resistant Epilepsy in Children

NCT02397863
View directory record Official record
Conditions
Epilepsy
Interventions
Cannabidiol (Epidiolex)
Drug
Lead sponsor
Augusta University
Other
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

NCT00256191
View directory record Official record
Conditions
Neoplasms, Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions
TPI 287 Injection
Drug
Lead sponsor
Cortice Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 14, 2007 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

NCT04150068
View directory record Official record
Conditions
HIV-1-infection
Interventions
Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
35
States / cities
Los Angeles, California • Palm Springs, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Point Prevalence Study of Multidrug-Resistant Organism Carriage by Healthcare Personnel

NCT01952158
View directory record Official record
Conditions
Multidrug Resistance
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional

Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT00091377
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, paclitaxel, phenoxodiol
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years to 120 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization

NCT03118232
View directory record Official record
Conditions
Hospitalization, Infection
Interventions
Chlorhexidine gluconate (CHG), Iodophor (10% povidone-iodine)
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
13,952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
28
States / cities
Anaheim, California • Bellflower, California • Capistrano Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting No phase listed Observational

ESIS in Pediatric DRE

NCT05469373
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
Sarah Katie Ihnen
Other
Eligibility
1 Year to 30 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 3 Interventional

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

NCT07184619
View directory record Official record
Conditions
Treatment-resistant Schizophrenia
Interventions
Evenamide 15 mg bid, Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Sentinel Cohort REACT

NCT05780801
View directory record Official record
Conditions
Multi-Drug Resistant Organism
Interventions
Allogeneic Microbiota in Glycerol (10%) (AMG)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1 Interventional

A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

NCT03549000
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS), Ovarian Cancer, Renal Cell Carcinoma (RCC), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
NZV930, PDR001, NIR178
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1Phase 2 Interventional

A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

NCT00841191
View directory record Official record
Conditions
Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms
Interventions
CNTO 328; Anti-interleukin-6 monoclonal antibody
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections

NCT03510351
View directory record Official record
Conditions
Pseudomonas Infections, Pseudomonas Aeruginosa
Interventions
Ceftolozane-Tazobactam
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 17, 2026, 5:15 AM EDT